<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

NVP-BGT226 - BGT 226

產(chǎn)品貨號

Axon 2029 CAS [1245537-68-1] MF C28H25F3N6O2.C4H4O4MW 650.60 Purity: 99% Soluble in DMSO Description Orally active dual PI3K/mTOR inhibitor; induces cell cycle arrest and regulates survivin gene expression in human pancreatic cancer cell lines; inhibits growth in common myeloma cell lines and primary myeloma cells at nanomolar concentrations in a time-dependent and dose-dependent manner References Certificates Categories Extra info KY Chang et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin. Cancer Res. 2011, 17(22), 7116-26. ? W Glienke et al. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012, 33(3), 757-765.? ? P Baumann et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012, 23(1), 131-138. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology PI3K mTOR PI3K-Akt-mTOR EC 2.7.11.1 Orally active dual PI3K/mTOR inhibitor Chemical name 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one maleate Parent CAS No. [915020-55-2] Order Size Unit Price Stock 5 mg €120.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

NVP-BGT226 - BGT 226

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2029

CAS [1245537-68-1]

MF C28H25F3N6O2.C4H4O4
MW 650.60

Purity: 99%
Soluble in DMSO

NVP-BGT226

Description

Orally active dual PI3K/mTOR inhibitor; induces cell cycle arrest and regulates survivin gene expression in human pancreatic cancer cell lines; inhibits growth in common myeloma cell lines and primary myeloma cells at nanomolar concentrations in a time-dependent and dose-dependent manner

KY Chang et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin. Cancer Res. 2011, 17(22), 7116-26.

W Glienke et al. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012, 33(3), 757-765.?

P Baumann et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012, 23(1), 131-138.

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Cycle Regulation Cell Signaling & Oncology PI3K mTOR PI3K-Akt-mTOR EC 2.7.11.1

Orally active dual PI3K/mTOR inhibitor

Chemical name

8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one maleate

Parent CAS No.

[915020-55-2]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>